Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Irinotecan Liposomes in Ewing Sarcoma
NCT06340204Phase 1Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitoxantrone hydrochloride liposome in Ewing sarcoma (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Mar 2024; status: recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT06340204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06340204.